KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Twist Bioscience (TWST) EBIT: 2018-2025

Historic EBIT for Twist Bioscience (TWST) over the last 8 years, with Sep 2025 value amounting to -$29.9 million.

  • Twist Bioscience's EBIT rose 16.95% to -$29.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$136.3 million, marking a year-over-year increase of 38.30%. This contributed to the annual value of -$136.3 million for FY2025, which is 38.30% up from last year.
  • Per Twist Bioscience's latest filing, its EBIT stood at -$29.9 million for Q3 2025, which was up 0.62% from -$30.1 million recorded in Q2 2025.
  • In the past 5 years, Twist Bioscience's EBIT registered a high of -$29.9 million during Q3 2025, and its lowest value of -$88.9 million during Q2 2024.
  • For the 3-year period, Twist Bioscience's EBIT averaged around -$48.1 million, with its median value being -$47.0 million (2023).
  • As far as peak fluctuations go, Twist Bioscience's EBIT plummeted by 70.59% in 2021, and later surged by 66.13% in 2025.
  • Twist Bioscience's EBIT (Quarterly) stood at -$55.9 million in 2021, then climbed by 20.22% to -$44.6 million in 2022, then declined by 5.26% to -$47.0 million in 2023, then climbed by 26.25% to -$34.6 million in 2024, then rose by 16.95% to -$29.9 million in 2025.
  • Its EBIT stands at -$29.9 million for Q3 2025, versus -$30.1 million for Q2 2025 and -$41.6 million for Q1 2025.